European Cancer Organisation


Friday 7 September 2018

12:00 - 13:00

Introductory Session: An ambitious agenda on cancer in Europe


In the wake of eurosceptic challenge, there is heightened impetus for the EU to ensure strong connection to the common aspirations of the citizen. Can a reenergised EU cancer agenda provide fresh demonstration of the benefits of structured cooperation between European countries? What should a more ambitious European agenda on cancer look like and consist of? What have we learned so far, and can examples from elsewhere, such as the USA’s Cancer Moonshot initiative, provide instructive lesson? 

Speakers include:

Dr Vytenis Andriukaitis
EU Commissioner for Health & Food Safety

Her Excellency Marie-Louise Coleiro Preca
President of Malta

Dr Dinah Singer
National Institute of Health, USA

Prof Mark Lawler
Queen's University Belfast, United Kingdom

Alojz Peterle MEP
President, MEPs Against Cancer


13:00 - 15:00

Outcomes Research: Adopting a 20 year mindset – the paradigm shift required


With cancer incidence rates expected to grow by 68% worldwide between 2012 and 2030, matching the promise of new science and treatment options with continually constrained public finance points to a more value-based landscape for rewarding innovation. It is right to demand more evidence and further certainty in respect to the real life benefits and outcomes achieved by current and potential models and modes of cancer care. It is to this need that outcomes research is addressed, a branch of public health research, which studies the outcomes of the structure and processes of the health care system on the health and well-being of patients and populations.

Yet obstacles remain in the path of progress, with identifiable gaps in the data infrastructure, research landscape, and international multi-stakeholder agreement on matters such as data sharing, ownership and protection.

Speakers include:

Prof Richard Sullivan
Kings College London, United Kingdom

Dr Bettina Ryll
Melanoma Patient Network Europe, Sweden

Dr Claudia Allemani
London School of Hygiene and Tropical Medicine, UK

John O'Donnell
Global VP, Health Economics and Outcomes Research, Bristol-Myers Squibb, USA


15:00 - 15:30

Refreshment Break

15:30 - 17:30

Big Data – who’s in charge?


Stakeholders recognise the benefits big data can bring to research and improvement of care and treatment for cancer. However its full realisation is unlikely to occur without leadership, responsibility, strategy, direction and implementation.

What aspects of leadership and responsibility appear to be presently missing in terms of bringing big data opportunities to fruition, to whom should these leadership roles be assigned, and where does accountability reside? Implicit within this discussion is considered reflection on whether the realisation of a big data-driven future in research requires the strong hand of government-led efforts, or whether responsibilities are of a more shared and distributed nature?

Speakers include:

Prof Mark Lawler
Queen's University Belfast, United Kingdom

Jan Geissler
CML Advocates Network, Germany

Dr Denis Lacombe
Director General, EORTC, Belgium

Dr Clifford Hudis
CEO, American Society of Clinical Oncology (ASCO)

Saturday 8 September 2018

9:00 - 10:30

Improving efficiency in cancer care: how can multidisciplinarity make a difference?


The session will:

  • Highlight latest research from All.Can on patient experience and perspective in respect to inefficiency in cancer care and opportunities for improvement

  • Explore the role of multidisciplinary cancer care in  addressing inefficiency in cancer care (e.g. reducing delays and unnecessary interventions, and improving outcomes)

  • Share early work by the Innovative Partnership on Action against Cancer (iPAAC) on meeting the challenge of waste and inefficiency in cancer care across Europe

  • Reflect on conclusions from 2018 research on waste and inefficiency in cancer care by the Swedish Institute for Health Economics (IHE)

Speakers include:

Kathy Oliver
International Brain Tumour Alliance, UK

Prof Bengt Jonsson
Stockholm School of Economics, Sweden

Prof Martine Piccart
Institut Jules Bordet, Belgium

Amadou Diarra
Global VP Policy Advocacy & Government Affairs, Bristol-Myers Squibb, USA

Dr Monica Bertagnolli
ASCO President, USA

Prof Hideo Baba
Japan Society of Clinical Oncology

10:30 - 11:00

Coffee Break

11:00 - 12:30

Integration of cancer care: the essential requirements


It is recognised that a multi-disciplinary and patient-centric approach is required to achieve integrated cancer care, central to attaining the best outcomes and quality of care for patients. But how do we move beyond the shared aspiration of integrated cancer care, to its real-life practice in daily reality? ECCO and primary care partner organisations have grappled with this question as part of a project to define “the essential requirements for primary care interventions throughout the cancer care pathway”. The outcomes of this work will be presented at the session, before inviting participants at the Summit to help finalise consensus resolutions on the topic via live voting technology.

The resolutions will include time-based targets for improvement, supported by assignment of responsibilities for achieving the goal, and underpinned by tools to aid implementation. Draft versions of the resolutions will be published for consultation in advance of the Summit.

Speakers include:

Dr Ian Banks
ECCO Patient Advisory Committee Chair, Belgium

Prof David Weller
University of Edinburgh, UK

Prof Peter Selby
University of Leeds, UK

Dr Tit Albreht
National Institute of Public Health, Slovenia

Dr Agnieszka Kolacinska
European Society of Surgical Oncology (ESSO)


12:00 - 13:30


13:30 -15:00

Quality in cancer care: how to demand it, measure it and implement it


We all want quality cancer care, but how can we describe what it consists of, acquire a reliable measure of the level of quality of cancer care being delivered, and succeed in implementing improvement?

To these three questions a range of expert contributors will share insights and advice ahead of the audience being invited to vote on a series of Summit resolutions intended to provide answers. The resolutions will include time-bound goals, assignment of responsibilities for their delivery, and a publicly available toolkit to support their implementation. Drafts of the resolutions will be published for consultation ahead of the Summit. Please visit here for further information.

Important reference will be made during the session to the ECCO Essential Requirements for Quality Cancer Care (ERQCCs) as well as the activities of the Innovative Partnership on Action against Cancer (iPAAC) in respect to improving governance of cancer care.

Speakers include:

Dr Alberto Costa
European School of Oncology, Italy

Geoffrey Henning

Prof Gunnar Saeter

Dr Elke Anklam
European Commission, Belgium 

Dr Simone Wesselmann
German Cancer Society, Germany

Dr Reg Waldeck
Head of Market Access, Bayer, USA


15:00 - 15:30

Coffee Break

15:30 - 17:30

Access and Value: It's about the entire cancer pathway


Led by Professor Yolande Lievens (President, ESTRO), ECCO has brought together a core group of experts to identify and reflect on existing methodologies for assessing value in respect to new pharmaceutical treatments. Following critical evaluation of the scales, including points of commonality and difference, the group will share with the Summit audience their initial reflections and recommendations about the application of value based healthcare principles more holistically, including, but not limited to, non-systemic oncology treatments such as surgery and radiotherapy. 

The existing value frameworks used in the oncology setting that have been assessed by the project include the ASCO Value Framework, the ESMO Magnitude of Clinical Benefit Scale and the NCCN Evidence Blocks.

The session will share the initial reflections on these value scales and invite wider stakeholder and audience contribution to the debate ahead of commencing a further stage of the project, which may include fuller articulation of a value scale that can translate for use in non-systemic oncology treatments.

The session will also provide opportunity for more general consideration of the value based healthcare agenda, its progression so far, policy learning from experiences of its application in different countries and settings, and desirable developments for the future.

Session moderator: Prof Richard Sullivan

Concluding remarks Prof Philip Poortmans, ECCO President

Speakers include:

Prof Yolande Lievens
Past President of the European Society for Radiotherapy and Oncology (ESTRO)

Dr Ajay Aggarwal
Institute of Cancer Policy, King’s College London

Prof Riccardo Audisio
Past President of the European Society of Surgical Oncology (ESSO)

Prof Elisabeth de Vries
University Medical Centre Groningen, Netherlands

Kathy Oliver
International Brain Tumour Alliance, UK

Part 2 of the session will examine how the role of professional care to cancer patients, and other interventions, can be better valued and recognised within national health systems.

Prof Lorenzo Derchi
President of the European Society of Radiology

Prof Andreas Charalambous
President-Elect of the European Oncology Nursing Society (EONS)

Dr Maria Die Trill
President of the International Psycho-Oncology Society (IPOS)

17:30 - 19:00

Putting a price on cancer medicines: the challenges and prospective solutions


The good news? Scientific advances are bringing forward new hope for cancer patients through emerging novel forms of treatment such as immunotherapy, targeted therapy and precision medicine. The bad news? Countries around the world continue to struggle with the headache of how to meet their cost.

This Summit session will invite a range of stakeholders to spell out the top challenges in the current pharmaceutical pricing and access environment, presenting concrete proposals for improvement.

Summit attendees will vote to record their preferences and responses to the proposals made.

Speakers include:

Eveline Scheres
Chair of the ECL Access to Cancer Medicines Taskforce

Nathalie Moll
Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA)

Prof Elisabeth de Vries
University Medical Centre Groningen, Netherlands

20:00 - 22:30


Sunday 9 September 2018

09:00 - 11:30

Survivorship: The next frontier of cancer care improvement

The ECCO 2018 European Cancer Summit session on Survivorship builds upon the important policy leadership activity of ECCO member EORTC in this area, including its biennial Survivorship Summit. 

Hearing from cancer survivors, legal experts and academics, the session will:
  • provide particular attention to the matter of financial discrimination encountered by cancer survivors,
  • highlight available means of policy redress, such as the French Government’s enactment of legal reforms rel="noopener noreferrer" to enshrine a ‘right to be forgotten’ for cancer patients in respect to what they are obliged to declare to loan providers and insurers
  • encourage the expression by stakeholders of consensus ambitions for reducing financial discrimination encountered by cancer survivors across rel="noopener noreferrer" all European countries. rel="noopener noreferrer" More information here:

Speakers include:

Janette Rawlinson
Cancer survivor and Patient Advocate, UK

Dr Marie Mesnil
University of Rennes, France

Šarunas Narbutas
Youth Cancer Europe

Prof Françoise Meunier
EORTC, Belgium


Refreshment Break

12:00- 13:00

Patrick Johnston Memorial Lecture

Prof Françoise Meunier
EORTC, Belgium




PLEASE NOTE: The programme schedule is subject to change.